Chronic Rejection of Cardiac Allografts Is Associated With Increased Lymphatic Flow and Cellular Trafficking

Background: Cardiac transplantation is an excellent treatment for end-stage heart disease. However, rejection of the donor graft, in particular, by chronic rejection leading to cardiac allograft vasculopathy, remains a major cause of graft loss. The lymphatic system plays a crucial role in the alloimmune response, facilitating trafficking of antigen-presenting cells to draining lymph nodes. The encounter of antigen-presenting cells with T lymphocytes in secondary lymphoid organs is essential for the initiation of alloimmunity. Donor lymphatic vessels are not anastomosed to that of the recipient during transplantation. The pathophysiology of lymphatic disruption is unknown, and whether this disruption enhances or hinders the alloimmune responses is unclear. Although histological analysis of lymphatic vessels in donor grafts can yield information on the structure of the lymphatics, the function following cardiac transplantation is poorly understood. Methods: Using single-photon emission computed tomography/computed tomography lymphoscintigraphy, we quantified the lymphatic flow index following heterotrophic cardiac transplantation in a murine model of chronic rejection. Results: Ten weeks following transplantation of a minor antigen (HY) sex-mismatched heart graft, the lymphatic flow index was significantly increased in comparison with sex-matched controls. Furthermore, the enhanced lymphatic flow index correlated with an increase in donor cells in the mediastinal draining lymph nodes; increased lymphatic vessel area; and graft infiltration of CD4+, CD8+ T cells, and CD68+ macrophages. Conclusions: Chronic rejection results in increased lymphatic flow from the donor graft to draining lymph nodes, which may be a factor in promoting cellular trafficking, alloimmunity, and cardiac allograft vasculopathy.

[1]  D. Zawieja,et al.  IL‐1β reduces tonic contraction of mesenteric lymphatic muscle cells, with the involvement of cycloxygenase‐2 and prostaglandin E2 , 2015, British Journal of Pharmacology.

[2]  S. D. De Serres,et al.  Innate immunity in solid organ transplantation: an update and therapeutic opportunities , 2015, Expert review of clinical immunology.

[3]  Josef Stehlik,et al.  The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  G. Koh,et al.  Inflammation-associated lymphangiogenesis: a double-edged sword? , 2014, The Journal of clinical investigation.

[5]  E. Sevick-Muraca,et al.  Lymphatic Vascular Response to Acute Inflammation , 2013, PloS one.

[6]  Yubin Kang,et al.  Using quantitative real-time PCR to determine donor cell engraftment in a competitive murine bone marrow transplantation model. , 2013, Journal of visualized experiments : JoVE.

[7]  B. Mehrara,et al.  CD4+ Cells Regulate Fibrosis and Lymphangiogenesis in Response to Lymphatic Fluid Stasis , 2012, PloS one.

[8]  A. Valujskikh,et al.  The Spleen Is the Major Source of Antidonor Antibody‐Secreting Cells in Murine Heart Allograft Recipients , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  W. Min,et al.  An overview of lymphatic vessels and their emerging role in cardiovascular disease , 2011, Journal of cardiovascular disease research.

[10]  B. Mehrara,et al.  Mechanisms of Lymphatic Regeneration after Tissue Transfer , 2011, PloS one.

[11]  K. Sunassee,et al.  SPECT/CT Lymphoscintigraphy of Heterotopic Cardiac Grafts Reveals Novel Sites of Lymphatic Drainage and T Cell Priming , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  K. Brown,et al.  Tertiary lymphoid organs in renal allografts can be associated with donor‐specific tolerance rather than rejection , 2011, European journal of immunology.

[13]  Yingjie Cui The role of lymphatic vessels in the heart. , 2010, Pathophysiology : the official journal of the International Society for Pathophysiology.

[14]  N. Sheerin,et al.  Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. , 2010, Kidney international.

[15]  K. Alitalo,et al.  Targeting Lymphatic Vessel Activation and CCL21 Production by Vascular Endothelial Growth Factor Receptor-3 Inhibition Has Novel Immunomodulatory and Antiarteriosclerotic Effects in Cardiac Allografts , 2010, Circulation.

[16]  A. Pathak,et al.  Lymphatic Injury and Regeneration in Cardiac Allografts , 2010, Transplantation.

[17]  J. Hughes,et al.  Restorative and rejection-associated lymphangiogenesis after renal transplantation: friend or foe? , 2009, Transplantation.

[18]  R. Lechler,et al.  Pathways of major histocompatibility complex allorecognition. , 2008, Current opinion in organ transplantation.

[19]  U. Lehmann,et al.  Recipient-Derived Neoangiogenesis of Arterioles and Lymphatics in Quilty Lesions of Cardiac Allografts , 2007, Transplantation.

[20]  M. Hyman,et al.  Heterotopic vascularized murine cardiac transplantation to study graft arteriopathy , 2007, Nature Protocols.

[21]  M. Di Nicola,et al.  Quilty Effect Has the Features of Lymphoid Neogenesis and Shares CXCL13–CXCR5 Pathway With Recurrent Acute Cardiac Rejections , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  D. Kerjaschki Lymphatic neoangiogenesis in renal transplants: a driving force of chronic rejection? , 2006, Journal of nephrology.

[23]  J. Fries,et al.  First year changes of myocardial lymphatic endothelial markers in heart transplant recipients. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[24]  F. Tacke,et al.  Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts , 2006, Nature Immunology.

[25]  F. Ginhoux,et al.  B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. , 2006, Immunity.

[26]  D. Kerjaschki,et al.  Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants , 2006, Nature Medicine.

[27]  K. Maruyama,et al.  Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. , 2005, The Journal of clinical investigation.

[28]  M. Sayegh,et al.  Transplantation 50 years later--progress, challenges, and promises. , 2004, The New England journal of medicine.

[29]  S. Schenk,et al.  Effects of T Cell Frequency and Graft Size on Transplant Outcome in Mice 1 , 2004, The Journal of Immunology.

[30]  Mark Coles,et al.  Transgenic mice with hematopoietic and lymphoid specific expression of Cre , 2003, European journal of immunology.

[31]  J. Kolls,et al.  Chimerism analysis in sex-mismatched murine transplantation using quantitative real-time PCR. , 2002, BioTechniques.

[32]  Shankar Srinivas,et al.  Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus , 2001, BMC Developmental Biology.

[33]  Fadi G Lakkis,et al.  Immunologic ‘ignorance’ of vascularized organ transplants in the absence of secondary lymphoid tissue , 2000, Nature Medicine.

[34]  K. Wood,et al.  Haematopoietic stem cells transduced with a single donor class I major histocompatibility complex gene can induce operational tolerance to fully allogeneic cardiac allografts. , 1999, Transplantation proceedings.

[35]  M. Botelho,et al.  Cardiac lymphatic dynamics after ischemia and reperfusion--experimental model. , 1998, Nuclear medicine and biology.

[36]  K. Wood,et al.  Pretransplant administration of a single donor class I major histocompatibility complex molecule is sufficient for the indefinite survival of fully allogeneic cardiac allografts: evidence for linked epitope suppression. , 1997, Transplantation.

[37]  J. Muz,et al.  Reestablishment of lymphatic drainage after canine lung transplantation. , 1993, The Journal of thoracic and cardiovascular surgery.

[38]  N. Hollenberg,et al.  Early Disappearance of Lymphatics Draining Ischemic Myocardium in the Dog , 1987, Angiology.

[39]  R. Corry,et al.  PRIMARILY VASCULARIZED ALLOGRAFTS OF HEARTS IN MICE: THE ROLE OF H‐2D, H‐2K, AND NON‐H-2 ANTIGENS IN REJECTION , 1973, Transplantation.

[40]  T. Saldeen,et al.  THE LYMPHATIC PATHWAYS FROM THE PERITONEAL CAVITY: A LYMPHANGIOGRAPHIC STUDY IN THE RAT. , 1964, Cancer research.

[41]  H. S. Bennett,et al.  The visualization of lymph-nodes and vessels by ethyl iodostearate (angiopac) and its effect on lymphoid tissue; a preliminary radiological and histological study. , 1954, The Journal of the Faculty of Radiologists. Faculty of Radiologists.

[42]  K. Wood,et al.  Gene Transfer and Tolerance Induction , 1998 .

[43]  A. J. Miller,et al.  The role of the lymphatic system in coronary atherosclerosis. , 1992, Medical hypotheses.

[44]  R. Superina,et al.  Assessment of primarily vascularized cardiac allografts in mice. , 1986, Transplantation.

[45]  D. Pressey Friend or FoE? , 1983, Nature.